Unexpected Findings on Weight Loss and Breast Cancer from International Study in JNCCN
New research found that weight loss after diagnosis was associated with worse outcomes for HER2-positive early breast cancer patients
News provided by
Share this article
PLYMOUTH MEETING, Pa., Feb. 16, 2021 /PRNewswire/ New research in the February 2021 issue of
JNCCN Journal of the National Comprehensive Cancer Network examined body mass index (BMI) data for people with HER2-positive early breast cancer, and found a 5% weight loss in patients over two years in was associated with worse outcomes. Weight gain over the same time period did not affect survival rates.
Date Time
Shaping National Public Health Policies With Science
CU Anschutz experts sit on NASEM committees, offering a ‘critical translational step’ in turning science into policy
Professors and faculty members at most research universities spend the bulk of their professional time in well-known academic pursuits: teaching, researching, collaborating with colleagues, and leading the next generation of experts in their respective fields. Less apparent are hundreds of hours some volunteer to present at conferences, provide testimony for policies, and collaborate on scientific committee work, publish papers, and review others’ work for publication.
One distinguished but often less publicized volunteer effort is chairing or sitting on a variety of committees within the National Academies of Sciences, Engineering and Medicine (NASEM). At the Colorado School of Public Health (ColoradoSPH), many faculty volunteer with NASEM committees, and in this role, they help to shape policies
Does Marijuana Help With Breast Cancer? By Barbara Brody
April Curtis has been living with stage IV breast cancer for 6 years. The cancer itself, as well as some of the treatments for it, have caused a variety of debilitating side effects, especially nausea and severe pain. For a while, her doctors tried to ease these issues with higher and higher doses of medication, including strong opiates, but she was still miserable. About 3 years ago, she decided to give marijuana a try.
“For nausea, it’s wonderful,” says Curtis, 39. “For pain, I can’t rely on it 100%, but it allows me to use a lower dose of opiates.”
Share:
Phase 2 Adaptive Trial Design to Evaluate VS-6766 Alone and in Combination with Defactinib With a Focus on KRAS-G12V Mutations
Trial Designed to Address Significant Unmet Medical Need in These Treatment-Resistant Tumors
Verastem Oncology to Seek FDA Accelerated Approval, Pending Trial Outcome
Verastem, Inc. (NASDAQ:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the initiation of a Phase 2 registration-directed clinical trial of VS-6766, its RAF/MEK inhibitor, alone and in combination with defactinib, its FAK inhibitor, in patients with KRAS mutant non-small cell lung cancer (NSCLC). Currently available options for patients with KRAS mutant NSCLC are associated with minimal efficacy, as well as resistance and toxicity issues. Our study will further elucidate the impact of VS-6766, alone or in combination with defactinib, in overcoming these challenges to improve outco